Insider Selling: Doximity (NYSE:DOCS) Director Sells 10,721 Shares of Company Stock

Doximity, Inc. (NYSE:DOCS) Director Timothy Cabral sold 10,721 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total value of $375,235.00. Following the transaction, the director directly owned 8,084 shares of the company’s stock, valued at approximately $282,940. This represents a 57.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Doximity Stock Up 1.6%

DOCS traded up $0.52 during midday trading on Monday, hitting $33.02. 3,072,633 shares of the company were exchanged, compared to its average volume of 3,886,933. The firm’s 50 day moving average price is $29.09 and its 200-day moving average price is $25.51. Doximity, Inc. has a 1-year low of $17.15 and a 1-year high of $55.96. The firm has a market capitalization of $5.89 billion, a P/E ratio of 45.87, a P/E/G ratio of 25.43 and a beta of 1.29.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.17. The company had revenue of $174.54 million during the quarter. Doximity had a return on equity of 15.80% and a net margin of 21.12%. During the same period in the previous year, the company posted $0.45 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts predict that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DOCS shares. Raymond James Financial reissued an “outperform” rating and set a $38.00 target price on shares of Doximity in a research report on Friday, October 16th. Zacks Research upgraded shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Freedom Capital lowered shares of Doximity from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Evercore set a $35.00 price objective on shares of Doximity in a research report on Tuesday, September 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $41.00 target price on shares of Doximity in a research note on Friday. Eight analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $30.45.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Analysts raised Doximity price targets to $40 and $34, while Needham reiterated its Buy rating—signals of continued optimism despite recent concerns. Price target raised to $40 Price target raised to $34 Needham Buy rating reiterated
• Neutral Sentiment: Truist maintained a Hold rating, reflecting a more cautious view alongside the bullish analyst calls. Truist keeps Hold rating
• Negative Sentiment: Several law firms publicized the same securities class action, with a November 16, 2026 lead-plaintiff deadline for investors who acquired shares from August 8, 2024, through May 13, 2026. The complaint alleges Doximity misrepresented revenue growth and market share and failed to disclose slowing sales, contracting net income, and changes in pharmaceutical customers’ advertising budgets. These remain allegations, but the litigation could create reputational and legal overhang. Shareholder alert and allegations

Institutional Investors Weigh In On Doximity

Several institutional investors and hedge funds have recently made changes to their positions in DOCS. Carmignac Gestion increased its holdings in Doximity by 127.8% during the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Doximity in the third quarter valued at approximately $28,858,000. Renaissance Technologies LLC lifted its holdings in shares of Doximity by 29.4% in the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after purchasing an additional 694,300 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Doximity by 24.7% in the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock valued at $65,022,000 after purchasing an additional 621,464 shares in the last quarter. Finally, Amundi boosted its position in shares of Doximity by 9,956.5% during the first quarter. Amundi now owns 569,095 shares of the company’s stock valued at $13,260,000 after buying an additional 563,436 shares during the last quarter. Institutional investors own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals.

The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.

Founded in 2010, Doximity primarily serves the U.S.